SKYLER JAY S 4

What Happened
Skyler Jay S, a director of Applied Therapeutics (APLT), reported dispositions totaling 328,690 shares on 2026-02-03 related to the company’s merger. The shares were converted/cancelled under the merger terms for a closing cash amount of $0.088 per share (net to the seller) plus one non-tradeable contingent value right (CVR) per share. The cash portion on 328,690 shares equals approximately $28,924.72. The disposals include both outstanding common shares and derivative awards (RSUs and options) that were vested, converted or cancelled as part of the transaction.

Key Details

• Transaction date on form: 2026-02-03 (Merger effective time per filing: 2026-01-28).
• Total shares disposed: 328,690 shares (breakdown: 65,000 shares of common stock; 263,690 shares from derivative awards — RSUs/options).
• Cash consideration: $0.088 per share (≈ $28,924.72 total) plus one non-tradeable CVR per share. Price reported as N/A on the Form 4 because shares were converted under the merger agreement.
• Derivative treatment: RSUs were deemed vested and converted into merger consideration; out‑of‑the‑money options were vested if applicable and any remaining out‑of‑the‑money options outstanding at the Effective Time were canceled for no consideration (per footnotes).
• Shares owned after the transaction: not disclosed in the filing.
• Filing date (accession): 2026-02-03. The Form 4 reports merger-related dispositions rather than open-market sales.

Context
These are merger-related dispositions (shares cancelled/converted into the merger consideration), not routine open-market sales. The reporting shows conversion to the merger consideration (cash + CVR) and the automatic treatment of equity awards under the merger agreement — so the transactions reflect corporate deal mechanics rather than an insider choosing to sell on the market.